top of page
Thymosin Alpha 1
Thymosin Alpha 1

Thymosin Alpha 1

$55.00Price
Size
5mg
10mg
Quantity

Thymosin Alpha-1

Thymosin Alpha-1 (Ta1/Thymalfasin/Zadaxin) is a synthetic 28-amino acid peptide identical to the naturally occurring thymic hormone. It's one of the most clinically validated immune peptides — over 11,000 patients studied across 30+ clinical trials, FDA orphan drug designations for four conditions, and approved in 35+ countries. Exceptional safety profile with less than 1% serious adverse events.

MECHANISM OF ACTION

Ta1 activates immune responses through multiple TLR pathways, enhances T-cell maturation in the thymus, stimulates natural killer (NK) cells, and modulates dendritic cell function and cytokine production. It provides balanced immune enhancement without excessive inflammation — it restores immune homeostasis rather than just amplifying immune activity.

POTENTIAL BENEFITS

  • Enhanced T-cell maturation and immune cell development

  • Increased NK cell activity and antiviral defense

  • Improved vaccine response, especially in elderly and immunocompromised

  • Reduced infection risk and faster recovery from illness

  • Mitigation of cytokine storms in severe infections

  • Protection against chemotherapy-induced bone marrow damage

  • Post-surgical immune recovery and reduced complications

  • Support for post-COVID immune restoration

  • Enhanced immune function during high stress or intense training

  • Anti-inflammatory effects without immunosuppression

WHY IT'S BEING RESEARCHED

Ta1 is being researched because it directly addresses thymic atrophy — the age-related decline in immune function that makes older adults vulnerable to infection and disease.

A 2024 comprehensive safety review across 11,000+ patients confirmed less than 1% serious adverse events, establishing it as exceptionally safe. A post-COVID study showed Ta1 restored immune homeostasis in lymphocytes with normalized T-cell populations and reduced inflammatory markers.

It's unique because it enhances immunity without causing excessive inflammation, making it valuable for both acute immune support and chronic immune restoration.

INTERESTING FACTS

  • Identical to the naturally occurring thymic hormone produced by the thymus gland

  • Only 28 amino acids — small enough for excellent bioavailability

  • Available in both injectable (1.6mg, 2x weekly) and nasal spray (500–1000mcg, 1–2x daily) formulations

  • Injectable route has extensive clinical data; nasal route is newer with less clinical validation

  • Approved in 35+ countries including China, Russia, and much of Europe

  • FDA orphan drug designations for four conditions

  • Works through multiple immune pathways simultaneously — not a single-target compound

  • Exceptional safety even in immunocompromised patients (except transplant recipients)

  • Effects visible within 1–2 weeks; maximum benefits by week 6–12

  • Can be used continuously for 6+ months without mandatory breaks

  • Synergizes well with vaccines and other immune-supporting peptides

STACKING THYMOSIN ALPHA-1 Strong synergies:

VIP for enhanced immune modulation

Both are immunomodulatory peptides that complement each other in regulating immune function. Synergistic benefits documented.

BPC-157 for immune support plus tissue repair

Ta1 enhances immune function while BPC-157 promotes tissue healing and growth factor signaling. Different mechanisms, complementary effects.

TB-500 for immune support plus tissue regeneration

Ta1 activates immune cells while TB-500 promotes angiogenesis and stem cell activation. Works well together for post-injury recovery.

Interferon for enhanced antiviral efficacy

Synergistic NK cell activation, particularly effective for hepatitis treatment. Monitor for increased fever and fatigue.

Vaccines

Ta1 enhances vaccine immunogenicity, especially beneficial in elderly and immunocompromised patients. Intended therapeutic effect.

Compatible stacks:

Testagen for bioregulation across multiple systems

Different targets (thymus vs pituitary), no negative interactions.

Thymalin for complementary thymic-axis immunity

Both target immune function but through different mechanisms (Ta1 via TLR signaling, Thymalin via epigenetic regulation).

KPV for balanced immune modulation

Ta1 enhances immune function while KPV reduces inflammation. Different mechanisms.

Monitor:

Corticosteroids

Ta1 blocks steroid-induced thymocyte apoptosis, potentially reducing the immunosuppressive effects of steroids. Discuss with healthcare provider if combining.



RESEARCH PURPOSES ONLY

NOT AVAILABLE FOR HUMAN CONSUMPTION

    bottom of page